Albert Bourla picks a new dealmaker to lead the hunt for more drugs to swell Pfizer’s pipeline
A new dealmaker is joining the executive crew at Pfizer.
The pharma giant says that McKinsey vet Aamir Malik is jumping on board as a new executive vice president and “chief business innovation officer.” He’s taking the place of John Young, who had earlier announced plans to retire from the pharma giant after a 34-year run.
Malik has a tough act to follow. In his sendoff, CEO Albert Bourla credited Young with establishing collaborations for the pharma giant that led to its incredibly profitable tie-up with BioNTech. That alliance has delivered a megablockbuster Covid-19 vaccine that promises to earn tens of billions of dollars.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.